WASHINGTON, DC – Today, we are one step closer to a world without polio. The Sabin Vaccine Institute, founded in memory of oral polio vaccine creator Dr. Albert Sabin, applauds the tremendous achievement by the global polio community in eradicating wild poliovirus type 3.
WASHINGTON, D.C. – The Sabin Vaccine Institute (Sabin) today announced that Dr. Filip Dubovsky, head of clinical engagement and policy at AstraZeneca, has joined its Board of Trustees.
WASHINGTON, D.C. – The Sabin Vaccine Institute (Sabin) today announced a funding award of $20.5 million with options for an additional $107.5 million from the Biomedical Advanced Research and Development Authority (BARDA) within the U.S. Department of Health and Human Services.
WASHINGTON, D.C. – The Sabin Vaccine Institute (Sabin) announces the appointment of three new members to its Board of Trustees. Joining the Board are Drs. Elizabeth Fox, Saad Omer and Jacqueline Shea, well-respected leaders whose range of skills and experience promise to advance Sabin’s aim to ensure all people, everywhere get the vaccines they need.
LONDON / WASHINGTON, D.C. – GSK and the Sabin Vaccine Institute (Sabin) today announced exclusive agreements for Sabin to advance the development of the prophylactic candidate vaccines against the deadly Ebola Zaire, Ebola Sudan and the closely related, but lesser known, Marburg virus.